View More View Less
  • 1 Semmelweis Egyetem, Általános Orvostudományi Kar II. Belgyógyászati Klinika Budapest Szentkirályi u. 46. 1088
  • 2 Magyar Tudományos Akadémia–Semmelweis Egyetem Molekuláris Medicina Kutatócsoport Budapest
Restricted access

Purchase article

USD  $25.00

1 year subscription (Individual Only)

USD  $1,070.00

Az érképződés fontos szerepet játszik számos betegség kialakulásában. A vascularis endothelnövekedési faktor központi fontosságú az élettani és a kóros érképződés folyamatában. A VEGF fokozott expressziója összefügg a daganatos érképződéssel, az áttétek kialakulásával és a tumorsejtek proliferációjával. A humán monoklonális anti-VEGF-antitest (bevacizumab) a hagyományos kemoterápia kiegészítéseként alkalmazva jó hatású lehet különböző daganatok kezelésében. Egyre több adat igazolja, hogy a bevacizumab javítja a betegek életkilátásait áttétet adó colorectalis carcinomában és előrehaladott hepatocellularis carcinomában. További vizsgálatok szükségesek az érképzést gátló kezelés hatékonyságának megítélésére egyéb tápcsatorna-daganatokban. Közleményünkben az emésztőszervi daganatok kezelésében alkalmazott, érképzést gátló készítményekkel kapcsolatos újabb eredményeket foglaljuk össze.

  • Folkman, J.: Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med., 1971, 285 , 1182–1186.

    Folkman J.: Tumor angiogenesis , 'Therapeutic implications ' (1971 ) 285 N. Engl. J. Med. : 1182 -1186.

    • Search Google Scholar
  • Ferrara, N., Mass, R. D., Campa, C. és mtsa: Targeting VEGF-A to treat cancer and age-related macular degeneration. Ann. Rev. Med., 2007, 58 , 491–504.

    Campa C. , 'Targeting VEGF-A to treat cancer and age-related macular degeneration ' (2007 ) 58 Ann. Rev. Med. : 491 -504.

    • Search Google Scholar
  • Ku, D. D., Zaleski, J. K., Liu, S. és mtsa: Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol., 1993, 265 , 586–592.

    Liu S. , 'Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries ' (1993 ) 265 Am. J. Physiol. : 586 -592.

    • Search Google Scholar
  • Park, J. E., Chen, H. H., Winer, J. és mtsai: Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. J. Biol. Chem., 1994, 275 , 26690–26695.

    Winer J. , 'Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR ' (1994 ) 275 J. Biol. Chem. : 26690 -26695.

    • Search Google Scholar
  • Soker, S., Takashima, S., Miao, H. Q. és mtsai: Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell, 1998, 92 , 735–745.

    Miao H. Q. , 'Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor ' (1998 ) 92 Cell : 735 -745.

    • Search Google Scholar
  • Carmeliet, P., Jain, R. K.: Angiogenesis in cancer and other diseases. Nature, 2000, 407 , 249–257.

    Jain R. K. , 'Angiogenesis in cancer and other diseases ' (2000 ) 407 Nature : 249 -257.

  • Jain, R. K.: Molecular regulation of vessel maturation. Nat. Med., 2003, 9 , 685–693.

    Jain R. K. , 'Molecular regulation of vessel maturation ' (2003 ) 9 Nat. Med. : 685 -693.

  • Jain, R. K.: Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 2005, 307 , 58–62.

    Jain R. K. , 'Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy ' (2005 ) 307 Science : 58 -62.

    • Search Google Scholar
  • Willett, C. G., Boucher, Y., di Tomaso, E. és mtsai: Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med., 2004, 10 , 145–147.

    Tomaso E. , 'Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer ' (2004 ) 10 Nat. Med. : 145 -147.

    • Search Google Scholar
  • Gridelli, C., Maione, P., Del Gaizo, F., Colantuoni, G. és mtsai: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist, 2007, 12 , 191–200.

    Colantuoni G. , 'Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer ' (2007 ) 12 Oncologist : 191 -200.

    • Search Google Scholar
  • Azad, N. S., Posadas, E. M., Kwitkowski, V. E. és mtsai: Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J. Clin. Oncol., 2008, 26 , 3709–3714.

    Kwitkowski V. E. , 'Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity ' (2008 ) 26 J. Clin. Oncol. : 3709 -3714.

    • Search Google Scholar
  • Salomon, D. S., Brandt, R., Ciardiello, F. és mtsai: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol., 1995, 19 , 183–232.

    Ciardiello F. , 'Epidermal growth factor-related peptides and their receptors in human malignancies ' (1995 ) 19 Crit. Rev. Oncol. Hematol. : 183 -232.

    • Search Google Scholar
  • Mahtani, R. L., Macdonald, J. S.: Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract. Oncologist, 2008, 13 , 39–50.

    Macdonald J. S. , 'Synergy between cetuximab and chemotherapy in tumors of the gastrointestinal tract ' (2008 ) 13 Oncologist : 39 -50.

    • Search Google Scholar
  • Petit, A. M., Rak, J., Hung, M. C. és mtsai: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors. Am. J. Pathol., 1997, 151 , 1523–1530.

    Hung M. C. , 'Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors ' (1997 ) 151 Am. J. Pathol. : 1523 -1530.

    • Search Google Scholar
  • Cunningham, D., Humblet, Y., Siena, S. és mtsai: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer. N. Engl. J. Med., 2004, 351 , 337–345.

    Siena S. , 'Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan refractory metastatic colorectal cancer ' (2004 ) 351 N. Engl. J. Med. : 337 -345.

    • Search Google Scholar
  • Yan, M., Plowman, G. D.: Delta-like 4/Notch signalling and its therapeutic implications. Clin. Cancer Res., 2007, 13 , 7243–7246.

    Plowman G. D. , 'Delta-like 4/Notch signalling and its therapeutic implications ' (2007 ) 13 Clin. Cancer Res. : 7243 -7246.

    • Search Google Scholar
  • Noguera-Troise, I., Daly, C., Papadopoulos, N. J. és mtsai: Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature, 2006, 444 , 1032–1037.

    Papadopoulos N. J. , 'Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis ' (2006 ) 444 Nature : 1032 -1037.

    • Search Google Scholar
  • Ridgway, J., Zhang, G., Wu, Y. és mtsai: Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature, 2006, 444 , 1083–1087.

    Wu Y. , 'Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis ' (2006 ) 444 Nature : 1083 -1087.

    • Search Google Scholar
  • Holash, J., Davis, S., Papadopoulos, N. és mtsai: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl. Acad. Sci. USA, 2002, 99 , 11393–11398.

    Papadopoulos N. , 'VEGF-Trap: a VEGF blocker with potent antitumor effects ' (2002 ) 99 Proc. Natl. Acad. Sci. USA : 11393 -11398.

    • Search Google Scholar
  • Schiffelers, R. M., Ansari, A., Xu, J. és mtsai: Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucl. Acids Res., 2004, 32 , 149.

    Xu J. , 'Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle ' (2004 ) 32 Nucl. Acids Res. : 149 -.

    • Search Google Scholar
  • Omura, K.: Advances in chemotherapy against advanced or metastatic colorectal cancer. Digestion, 2008, 77 , 13–22.

    Omura K. , 'Advances in chemotherapy against advanced or metastatic colorectal cancer ' (2008 ) 77 Digestion : 13 -22.

    • Search Google Scholar
  • Scheithauer, W., Rosen, H., Kornek, G. V. és mtsai: Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. BMJ, 1993, 306 , 752–755.

    Kornek G. V. , 'Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer ' (1993 ) 306 BMJ : 752 -755.

    • Search Google Scholar
  • Thirion, P., Michiels, S., Pignon, J. P.: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J. Clin. Oncol., 2004, 22 , 3766–3775.

    Pignon J. P. , 'Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis ' (2004 ) 22 J. Clin. Oncol. : 3766 -3775.

    • Search Google Scholar
  • Saltz, L. B., Cox, J. V., Blanke, C. és mtsai: Irinotecan Study Group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2000, 343 , 905–914.

    Blanke C. , 'Irinotecan Study Group: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer ' (2000 ) 343 N. Engl. J. Med. : 905 -914.

    • Search Google Scholar
  • De Gramont, A., Figer, A., Seymour, M. és mtsai: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol., 2000, 18 , 2938–2947.

    Seymour M. , 'Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer ' (2000 ) 18 J. Clin. Oncol. : 2938 -2947.

    • Search Google Scholar
  • Tournigand, C. A. T., Achille, E. és mtsai: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol., 2004, 22 , 229–237.

    Achille E. , 'FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study ' (2004 ) 22 J. Clin. Oncol. : 229 -237.

    • Search Google Scholar
  • Hurwitz, H., Fehrenbacher, L., Novotny, W. és mtsai: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med., 2004, 350 , 2335–2342.

    Novotny W. , 'Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer ' (2004 ) 350 N. Engl. J. Med. : 2335 -2342.

    • Search Google Scholar
  • Saltz, L. B., Clarke, S., Díaz-Rubio, E. és mtsai: Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J. Clin. Oncol., 2008, 26 , 2013–2019.

    Díaz-Rubio E. , 'Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study ' (2008 ) 26 J. Clin. Oncol. : 2013 -2019.

    • Search Google Scholar
  • Van Cutsem, E., Nowacki, M., Lang, I. és mtsai: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial. J. Clin. Oncol., 2007, 25 , A4000.

    Lang I. , 'Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): the CRYSTAL trial ' (2007 ) 25 J. Clin. Oncol. : A4000 -.

    • Search Google Scholar
  • De Gramont, A., Krulik, M., Cady, J. és mtsai: High dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer. Eur. J. Cancer Clin. Oncol., 1988, 24 , 1499–1503.

    Cady J. , 'High dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer ' (1988 ) 24 Eur. J. Cancer Clin. Oncol. : 1499 -1503.

    • Search Google Scholar
  • Wang, J. C.: DNA topoisomerases. Ann. Rev. Biochem., 1985, 54 , 665–697.

    Wang J. C. , 'DNA topoisomerases ' (1985 ) 54 Ann. Rev. Biochem. : 665 -697.

  • De Gramont, A., Tournigand, C., Louvet, C. és mtsai: GERCOD: Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in retreated patients with metastatic advanced cancer. Rev. Med. Intern., 1997, 18 , 769–775.

    Louvet C. , 'GERCOD: Oxaliplatin, folinic acid and 5-fluorouracil (folfox) in retreated patients with metastatic advanced cancer ' (1997 ) 18 Rev. Med. Intern. : 769 -775.

    • Search Google Scholar
  • Ferrara, N., Hillan, K. J., Novotny, W.: Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem. Biophys. Res. Commun., 2005, 333 , 328–335.

    Novotny W. , 'Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy ' (2005 ) 333 Biochem. Biophys. Res. Commun. : 328 -335.

    • Search Google Scholar
  • Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L. és mtsai: Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J. Clin. Oncol., 2003, 21 , 60–65.

    Fehrenbacher L. , 'Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer ' (2003 ) 21 J. Clin. Oncol. : 60 -65.

    • Search Google Scholar
  • Reinacher-Schick, A., Pohl, M., Schmiegel, W.: Drug insight: antiangiogenic therapies for gastrointestinal cancers – focus on monoclonal antibodies. Nat. Clin. Pract. Gastroenterol. Hepatol., 2008, 5 , 250–267.

    Schmiegel W. , 'Drug insight: antiangiogenic therapies for gastrointestinal cancers – focus on monoclonal antibodies ' (2008 ) 5 Nat. Clin. Pract. Gastroenterol. Hepatol. : 250 -267.

    • Search Google Scholar
  • Fuchs, C. S., Marshall, J., Mitchell, E. és mtsai: Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J. Clin. Oncol., 2007, 25 , 4779–4786.

    Mitchell E. , 'Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study ' (2007 ) 25 J. Clin. Oncol. : 4779 -4786.

    • Search Google Scholar
  • Hochster, H. S., Hart, L. L., Ramanathan, R. K. és mtsai: Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J. Clin. Oncol., 2008, 26 , 3523–3529.

    Ramanathan R. K. , 'Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study ' (2008 ) 26 J. Clin. Oncol. : 3523 -3529.

    • Search Google Scholar
  • Mancuso, M. R., Davis, R., Norberg, S. M. és mtsai: Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J. Clin. Invest., 2006, 116 , 2610–2621.

    Norberg S. M. , 'Rapid vascular regrowth in tumors after reversal of VEGF inhibition ' (2006 ) 116 J. Clin. Invest. : 2610 -2621.

    • Search Google Scholar
  • Giantonio, B. J., Catalano, P. J., Meropol, N. J. és mtsai: Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J. Clin. Oncol., 2007, 25 , 1539–1544.

    Meropol N. J. , 'Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 ' (2007 ) 25 J. Clin. Oncol. : 1539 -1544.

    • Search Google Scholar
  • Grothey, A., Sugrue, M., Hedrick, E. és mtsai: Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE). J. Clin. Oncol., 2007, 25 , A4036.

    Hedrick E. , 'Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): results from a large observational study (BRiTE) ' (2007 ) 25 J. Clin. Oncol. : A4036 -.

    • Search Google Scholar
  • Drixler, T. A., Vogten, M. J., Ritchie, E. D. és mtsai: Liver regeneration is an angiogenesis-associated phenomenon. Ann. Surg., 2002, 236 , 703–711.

    Ritchie E. D. , 'Liver regeneration is an angiogenesis-associated phenomenon ' (2002 ) 236 Ann. Surg. : 703 -711.

    • Search Google Scholar
  • Scappaticci, F. A., Fehrenbacher, L., Cartwright, T. és mtsai: Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol., 2005, 91 , 173–180.

    Cartwright T. , 'Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab ' (2005 ) 91 J. Surg. Oncol. : 173 -180.

    • Search Google Scholar
  • Saltz, L. B., Lenz, H. J., Kindler, H. L. és mtsai: Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan refractory colorectal cancer: the BOND-2 study. J. Clin. Oncol., 2007, 25 , 4557–4561.

    Kindler H. L. , 'Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan refractory colorectal cancer: the BOND-2 study ' (2007 ) 25 J. Clin. Oncol. : 4557 -4561.

    • Search Google Scholar
  • Hecht, J. R., Chidiac, T., Mitchell, E. és mtsai: An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC). Ann. Oncol., 2007, 18 , A0033.

    Mitchell E. , 'An interim analysis of efficacy and safety from a randomized controlled trial of panitumumab with chemotherapy plus bevacizumab (Bev) for metastatic colorectal cancer (mCRC) ' (2007 ) 18 Ann. Oncol. : A0033 -.

    • Search Google Scholar
  • El-Serag, H. B., Davila, J. A., Petersen, N. J. és mtsa: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med., 2003, 139 , 817–823.

    Petersen N. J. , 'The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update ' (2003 ) 139 Ann. Intern. Med. : 817 -823.

    • Search Google Scholar
  • Llovet, J. M., Ricci, S., Mazzaferro, V. és mtsai: Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med., 2008, 354 , 420–422.

    Mazzaferro V. , 'Sorafenib in advanced hepatocellular carcinoma ' (2008 ) 354 N. Engl. J. Med. : 420 -422.

    • Search Google Scholar
  • Schwartz, J. D., Schwartz, M., Lehrer, D. és mtsai: Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein. J. Clin. Oncol., 2006, 24 , 4144.

    Lehrer D. , 'Bevacizumab in unresectable hepatocellular carcinoma (HCC) for patients without metastasis and without invasion of the portal vein ' (2006 ) 24 J. Clin. Oncol. : 4144 -.

    • Search Google Scholar
  • Zhu, A. X., Blaszkowsky, L. S., Ryan, D. P. és mtsai: Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J. Clin. Oncol., 2006, 24 , 1898–1903.

    Ryan D. P. , 'Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma ' (2006 ) 24 J. Clin. Oncol. : 1898 -1903.

    • Search Google Scholar
  • Thomas, M. B., Chadha, R., Iwasaki, M. és mtsai: The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). J. Clin. Oncol., 2007, 25 , 4567.

    Iwasaki M. , 'The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC) ' (2007 ) 25 J. Clin. Oncol. : 4567 -.

    • Search Google Scholar
  • Kleespies, A., Bruns, C. J., Jauch, K. W.: Clinical significance of VEGF-A, -C, and -D expression in esophageal malignancies. Onkologie, 2005, 28 , 281–288.

    Jauch K. W. , 'Clinical significance of VEGF-A, -C, and -D expression in esophageal malignancies ' (2005 ) 28 Onkologie : 281 -288.

    • Search Google Scholar
  • Shah, M. A., Ramanathan, R. K., Ilson, D. H. és mtsai: Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J. Clin. Oncol., 2006, 24 , 5201–5206.

    Ilson D. H. , 'Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma ' (2006 ) 24 J. Clin. Oncol. : 5201 -5206.

    • Search Google Scholar
  • Burris, H. A., Moore, M. J., Andersen, J. és mtsai: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol., 1997, 15 , 2403–2413.

    Andersen J. , 'Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial ' (1997 ) 15 J. Clin. Oncol. : 2403 -2413.

    • Search Google Scholar
  • Kindler, H. L., Friberg, G., Singh, D. A. és mtsai: Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol., 2005, 23 , 8033–8040.

    Singh D. A. , 'Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer ' (2005 ) 23 J. Clin. Oncol. : 8033 -8040.

    • Search Google Scholar
  • Kindler, H. L., Niedzwiecki, D., Hollis, E. és mtsai: A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB). J. Clin. Oncol., 2007, 25 , 4508.

    Hollis E. , 'A double-blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): a preliminary analysis of Cancer and Leukemia Group B (CALGB) ' (2007 ) 25 J. Clin. Oncol. : 4508 -.

    • Search Google Scholar
  • Moore, M. J., Goldstein, D., Hamm, J. és mtsai: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol., 2007, 25 , 1960–1966.

    Hamm J. , 'Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group ' (2007 ) 25 J. Clin. Oncol. : 1960 -1966.

    • Search Google Scholar